 |
|
|
| |
On-treatment HCV RNA as a Predictor of Sustained Virologic Response in HCV Genotype 3-Infected Patients Treated With Daclatasvir and Sofosbuvir: Analysis of the Phase 3 ALLY-3 Study
|
| |
| |
Reported by Jules Levin
DDW 2015 May 16-19 Wash DC
Kowdley K,1 Nelson D,2 Lalezari J,3 Box T,4 Gitlin N,5 Poleynard G,6 Rabinovitz M,7 Ravendhran N,8 Sheikh A,9 Siddique A,10 Bhore R,11 Yin PD,12 Noviello S,11 Rana K12
1Swedish Medical Center, Seattle, WA, USA; 2University of Florida, Gainesville, FL, USA; 3Quest Clinical Research, San Francisco, CA, USA; 4Clinical Research Centers of America, LLC, Murray, UT, USA; 5Atlanta Gastroenterology Associates, Atlanta, GA, USA;
6Digestive Health Specialists, Winston-Salem, NC, USA; 7University of Pittsburgh, Pittsburgh, PA, USA; 8Digestive Disease Associates, Baltimore, MD, USA; 9Gastrointestinal Specialists of Georgia, Marietta, GA, USA; 10Virginia Mason Medical Center, Seattle, WA, USA; 11Bristol-Myers Squibb Research and Development, Princeton, NJ, USA; 12Bristol-Myers Squibb Research and Development, Wallingford, CT, USA
|
| |
|
|
|
|
|
